GO
Loading...

AstraZeneca PLC

More

  • *AstraZeneca shares up 1.5 percent. LONDON, Jan 14- AstraZeneca's blood-thinning drug Brilinta cut the risk of death or heart attack in patients with a history of previous attacks, according to a major clinical trial that will boost hopes for the product. But AstraZeneca Chief Executive Pascal Soriot has made it a top priority and the company flagged Brilinta's...

  • ZURICH/ LOS ANGELES Jan 12- Roche Holding will acquire a majority stake in molecular and genomic analysis business Foundation Medicine, it said on Monday, signalling its determination to expand in cancer immunotherapy by paying a hefty mark-up on the U.S. company's current price. The deal will help the world's largest maker of cancer drugs push ahead in...

  • Cramer Remix: Party with these rock star stocks Thursday, 8 Jan 2015 | 7:15 PM ET
    Jim Cramer on Mad Money.

    "Mad Money" host Jim Cramer on the players that could keep tearing it up in 2015.

  • Germany overtakes UK in corporate executive pay Monday, 5 Jan 2015 | 7:01 PM ET

    Germany has overtaken the UK as Europe's top-paid corporate executives, partly reflecting public and investor pressure on remuneration in UK companies. The Financial Times reports.

  • Tax inversion anyone? A year in M&A Monday, 29 Dec 2014 | 1:20 AM ET

    Mergers and acquisitions broke a seven-year losing streak in 2014, with $3.48 trillion worth of deals. CNBC looks at some of the year's highlights.

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • Dec 22- The U.S. Food and Drug Administration approved Bristol-Myers Squibb Co's skin cancer drug, more than three months before the scheduled review date. The drug is the second PD-1 inhibitor to be approved by the FDA, the first being Merck& Co Inc's Keytruda in September. The FDA was scheduled to review the drug on March 30.

  • Fear factor fades as global M&A hits 7-year high Monday, 22 Dec 2014 | 5:47 AM ET

    CEOs got their deal-making mojo back in 2014, emboldened by a clearer outlook for their businesses to take M&As to their highest level since 2007.

  • Dec 19- Cubist Pharmaceutical Inc's drug to treat complicated urinary tract and intra-abdominal infections won U.S. approval on Friday, highlighting the regulator's interest in tackling the growing threat of the so-called superbugs. Zerbaxa is the fourth new antibacterial drug approved by the FDA this year. The agency approved Actavis Plc's Dalvance in...

  • Dec 19- AstraZeneca Plc's ovarian cancer drug has been granted an accelerated approval by the U.S. health regulator, a day after the treatment was approved by the European Commission. AstraZeneca expects potential sales of around $2 billion a year from the drug. London- based AstraZeneca's U.S.-listed shares were down about 1 percent at $71.41 in afternoon...

  • Dec 19- AstraZeneca Plc's ovarian cancer drug has been granted an accelerated approval by the U.S. health regulator, a day after it was approved by the European Commission. An advisory panel to the U.S. Food and Drug Administration had voted in June against granting an accelerated approval to the drug, Lynparza, citing inadequate data. Lynparza aims to treat...

  • Spain's Almirall gains on report of Actavis interest Friday, 19 Dec 2014 | 12:29 PM ET

    Dec 19- Shares in Spanish drugmaker Almirall jumped 9 percent on Friday after a Bloomberg report of potential takeover interest from Actavis. Almirall played down the report, saying in a regulatory filing that "the news is untrue." Almirall, with a market value of 2.3 billion euros, recently sold its respiratory business to AstraZeneca, while Actavis is in the...

  • Dec 17- Tetraphase Pharmaceuticals Inc said its antibiotic to treat complicated intra-abdominal infections was as effective as Merck& co Inc's ertapenem in a late-stage study. Tetraphase is also testing the drug against Johnson& Johnson's levofloxacin to treat complicated urinary tract infections in another late-stage study, the results of which are...

  • LONDON, Dec 12- Britain has all the right ingredients for an M&A boom, upbeat company bosses, a vibrant economy and a buoyant stock market, but dealmaking is lagging behind the rest of the world. In Britain, although M&A activity is up compared to 2013, it has been flat for the last five years. Ten years ago, dealmaking in Britain, Europe's financial hub and home to some of...

  • ZURICH, Dec 12- Novartis said on Friday its experimental psoriasis drug Cosentyx was better at clearing the rough skin patches associated with the disease than Johnson& Johnson's Stelara. The data follows results last year showing Cosentyx, also known as secukinumab, was superior to Amgen's Embrel in a head-to-head study. Other drugmakers working on new...

  • TEL AVIV, Dec 11- Teva Pharmaceutical Industries forecast 2015 revenue below analysts' expectations, due to adverse foreign exchange moves and generic competition for its best-selling multiple sclerosis treatment Copaxone. There are two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's Sandoz Inc and Momenta...

  • LONDON, Dec 10- Drugmakers are finally getting more bang for their scientific buck, with the rate of return on pharmaceutical research and development increasing for the first time since 2010.. So far this year the U.S. Food and Drug Administration, which acts as gatekeeper to the world's biggest market, has approved 35 new products, up from 27 in the whole of 2013...

  • Best biotech trades on ASH meeting: Kensho Monday, 8 Dec 2014 | 12:31 PM ET

    Three small-cap drug firms are consistently the best biotech performers following the start of the American Society of Hematology's annual meeting.

  • Dec 5- A Massachusetts jury has found that an agreement between AstraZeneca Plc and Ranbaxy Laboratories Ltd to delay the launch of a generic version of AstraZeneca's heartburn drug Nexium was not anticompetitive. AstraZeneca and an attorney for Ranbaxy released statements saying they were pleased with the verdict. The lawsuit, which began in 2012,...